Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| classical monocyte | 21 studies | 29% ± 11% | |
| plasmacytoid dendritic cell | 16 studies | 27% ± 8% | |
| non-classical monocyte | 14 studies | 26% ± 10% | |
| dendritic cell | 13 studies | 27% ± 15% | |
| oligodendrocyte | 12 studies | 33% ± 12% | |
| monocyte | 11 studies | 26% ± 10% | |
| conventional dendritic cell | 10 studies | 22% ± 11% | |
| microglial cell | 9 studies | 30% ± 12% | |
| myeloid cell | 8 studies | 27% ± 7% | |
| macrophage | 8 studies | 30% ± 13% | |
| B cell | 7 studies | 19% ± 2% | |
| neutrophil | 7 studies | 27% ± 7% | |
| retinal rod cell | 7 studies | 39% ± 15% | |
| oligodendrocyte precursor cell | 6 studies | 32% ± 12% | |
| endothelial cell | 5 studies | 25% ± 6% | |
| mononuclear phagocyte | 4 studies | 21% ± 3% | |
| memory B cell | 4 studies | 20% ± 3% | |
| naive B cell | 4 studies | 17% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 100% | 13920.94 | 2641 / 2642 | 100% | 285.11 | 704 / 705 |
| lung | 100% | 7462.20 | 577 / 578 | 77% | 17.56 | 892 / 1155 |
| breast | 66% | 1345.27 | 303 / 459 | 88% | 20.60 | 987 / 1118 |
| prostate | 71% | 1628.31 | 174 / 245 | 71% | 11.82 | 358 / 502 |
| uterus | 85% | 4773.81 | 145 / 170 | 55% | 10.98 | 251 / 459 |
| intestine | 80% | 2404.54 | 772 / 966 | 44% | 8.24 | 232 / 527 |
| esophagus | 69% | 2705.96 | 1004 / 1445 | 51% | 8.64 | 94 / 183 |
| ovary | 61% | 1740.08 | 110 / 180 | 53% | 7.85 | 227 / 430 |
| thymus | 55% | 1175.38 | 360 / 653 | 54% | 9.03 | 329 / 605 |
| bladder | 48% | 1352.81 | 10 / 21 | 60% | 14.20 | 304 / 504 |
| adrenal gland | 82% | 1974.61 | 211 / 258 | 25% | 3.41 | 57 / 230 |
| stomach | 46% | 1009.91 | 165 / 359 | 59% | 13.07 | 170 / 286 |
| skin | 18% | 300.60 | 321 / 1809 | 86% | 36.08 | 407 / 472 |
| kidney | 25% | 470.38 | 22 / 89 | 76% | 23.68 | 688 / 901 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 136.01 | 29 / 29 |
| spleen | 100% | 9784.17 | 241 / 241 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 100% | 8.64 | 1 / 1 |
| peripheral blood | 100% | 28175.31 | 928 / 929 | 0% | 0 | 0 / 0 |
| adipose | 92% | 2561.48 | 1102 / 1204 | 0% | 0 | 0 / 0 |
| pancreas | 2% | 45.80 | 6 / 328 | 84% | 24.11 | 149 / 178 |
| tonsil | 0% | 0 | 0 / 0 | 73% | 22.19 | 33 / 45 |
| blood vessel | 59% | 1607.04 | 794 / 1335 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 56% | 12.01 | 45 / 80 |
| liver | 7% | 116.34 | 16 / 226 | 18% | 2.78 | 72 / 406 |
| heart | 15% | 275.01 | 132 / 861 | 0% | 0 | 0 / 0 |
| muscle | 0% | 1.64 | 1 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_1901222 | Biological process | regulation of non-canonical NF-kappaB signal transduction |
| GO_0045667 | Biological process | regulation of osteoblast differentiation |
| GO_0046330 | Biological process | positive regulation of JNK cascade |
| GO_0007249 | Biological process | canonical NF-kappaB signal transduction |
| GO_0007165 | Biological process | signal transduction |
| GO_0048872 | Biological process | homeostasis of number of cells |
| GO_0045860 | Biological process | positive regulation of protein kinase activity |
| GO_0045670 | Biological process | regulation of osteoclast differentiation |
| GO_1901223 | Biological process | negative regulation of non-canonical NF-kappaB signal transduction |
| GO_0046849 | Biological process | bone remodeling |
| GO_0050821 | Biological process | protein stabilization |
| GO_0031954 | Biological process | positive regulation of protein autophosphorylation |
| GO_0001501 | Biological process | skeletal system development |
| GO_0033137 | Biological process | negative regulation of peptidyl-serine phosphorylation |
| GO_0001503 | Biological process | ossification |
| GO_0043065 | Biological process | positive regulation of apoptotic process |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0000776 | Cellular component | kinetochore |
| GO_0032991 | Cellular component | protein-containing complex |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005794 | Cellular component | Golgi apparatus |
| GO_0005829 | Cellular component | cytosol |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0004672 | Molecular function | protein kinase activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | RASSF2 |
| Protein name | Ras association domain-containing protein 2 |
| Synonyms | CENP-34 KIAA0168 |
| Description | FUNCTION: Potential tumor suppressor. Acts as a KRAS-specific effector protein. May promote apoptosis and cell cycle arrest. Stabilizes STK3/MST2 by protecting it from proteasomal degradation. . |
| Accessions | ENST00000379376.2 [P50749-1] P50749 ENST00000379400.8 [P50749-1] |